Key statistics dashboard for PMGC Holdings Inc. (ELAB). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists.
Stock Data
| Price | $4.77 |
| Market Cap | $2M |
| Beta | 0.71 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.00 |
| Price / Book | 0.14 |
| P/S | 0.84 |
| P/FCF | -0.24 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 10.31% |
| EBIT Margin | -485.72% |
| EBITDA Margin | -464.01% |
| Operating Margin | -477.02% |
| Net Margin | -522.97% |
Financial Health
| Current Ratio | 1.36 |
| Quick Ratio | 1.30 |
| Cash Ratio | 1.18 |
| Debt / Equity | 0.83 |
| Debt / Assets | 38.06% |
| Interest Coverage | -5.56 |
Per-Share Data
| Revenue per share | 5.29 |
| Book Value per share | 34.32 |
| Cash per share | 38.54 |
| FCF per share | -18.43 |
| Tangible Book Value per share | 15.81 |
| Dividend per share | 0.00 |
Related companies: ATXI · BCTXZ · DRMA · MLEC · NCEL · NKGN · PBM
Explore sector: Healthcare · Biotechnology
More sections of ELAB: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks